Table 1.
Main characteristics and diagnostic details of included cases.
| Case | Article | Country | Age | Sex | Tumor type | ICIs | Time of GBS onset after the initiation treatment (week) | Time to neurological plateau (days) | GBS diagnosis |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Muralikrishnan, S et al. [14] | USA | 65 | Female | Melanoma | Pembrolizumab | 4 weeks | 44 | Clinical+CSF+electrophysiology |
| 2 | Han, C et al. [15] | China | 55 | Male | RCC | Pembrolizumab | 16 weeks | No mention | Clinical+CSF+electrophysiology |
| 3 | Arora, A et al. [16] | USA | 70 | Male | Melanoma and prostate cancer | Pembrolizumab | 12 weeks | 16 | Clinical+CSF+electrophysiology |
| 4 | Yuen, C et al. [17] | USA | 66 | Male | Melanoma | Nivolumab | 12 days (1.7 weeks) | 34 | Clinical+CSF+electrophysiology |
| 5 | Pomerantz, M et al. [18] | Italy | 58 | Male | SCLC | A combination of nivolumab and pembrolizumab | 59 days (8.4 weeks) | No mention | Clinical+CSF+electrophysiology |
| 6 | Pierrard, J et al. [19] | Belgium | 70 | Male | Urothelial carcinoma | Nivolumab | 59 weeks | 14 | Clinical+CSF+electrophysiology |
| 7 | McNeill, C. J et al. [20] | UK | 68 | Male | RCC | Nivolumab | 8 weeks | 13 | Clinical+CSF+electrophysiology |
| 8 | Kyriazoglou, A et al. [22] | Greece | 74 | Male | Bladder cancer | Nivolumab | 8 weeks | 15 | Clinical+CSF+electrophysiology |
| 9 | Mazzaschi, G et al. [21] | Italy | 80 | Male | Lung adenocarcinoma | Nivolumab | 12 days (1.7 weeks) |
22 | Clinical+CSF+electrophysiology |
| 10 | Gravbrot, N et al. [23] | USA | 71 | Male | Melanoma | Ipilimumab | 10 weeks | Several days | Clinical+CSF+electrophysiology |
| 11 | Wilson, R et al. [24] | UK | 52 | Male | Melanoma | Nivolumab Ipilimumab |
4 weeks | 7 | Clinical+CSF+electrophysiology |
| 12 | Thapa, B et al. [25] | USA | 60 | Male | Lung adenocarcinoma | Nivolumab | 14 weeks | No mention | Clinical+CSF+electrophysiology |
| 13 | Ong, S et al. [26] | UK | 66 | Male | Lung adenocarcinoma | Pembrolizumab | 6.5 weeks | 16 | Clinical+electrophysiology |
| 14 | Nukui, T et al. [27] | Japan | 45 | Male | Nasal cancer | Nivolumab | 10 weeks | 14 | Clinical+CSF+electrophysiology |
| 15 | Manam, R et al. [28] | USA | 73 | Male | Lung adenocarcinoma | Pembrolizumab | 3 weeks | No mention | Clinical+CSF |
| 16 | Manam, R et al. [28] | USA | 81 | Male | Melanoma | Pembrolizumab | 10 weeks | No mention | Clinical+CSF+electrophysiology |
| 17 | Garcia, C. A et al. [29] | USA | 55 | Male | Melanoma | Ipilimumab | 6 weeks | No mention | Clinical+CSF+electrophysiology |
| 18 | Fukumoto, Y et al. [30] | Japan | 66 | Male | NSCLC | Nivolumab | 3 weeks | 16 | Clinical+CSF+electrophysiology |
| 19 | Cafuir, L et al. [31] | USA | 42 | Male | Melanoma | Ipilimumab | 10 weeks | 13 | Clinical + CSF + electrophysiology |
| 20 | Baird-Gunning, J. J. D et al. [31] | Australia | 58 | Female | Melanoma | Nivolumab Ipilimumab |
10 days (1.4 weeks) | 12 | Clinical+CSF+electrophysiology |
| 21 | Supakornnumporn, S et al. [33] | USA | 77 | Male | Melanoma | Nivolumab Ipilimumab |
10 weeks | 14 | Clinical+CSF+electrophysiology |
| 22 | Schneiderbauer, R et al. [34] | German | 51 | Male | Melanoma | Nivolumab | 20 weeks | No mention | Clinical+CSF+electrophysiology |
| 23 | Patel, R. J et al. [35] | USA | 71 | Male | Melanoma | Ipilimumab | 10 weeks | 10 | Clinical+electrophysiology |
| 24 | Kelly Wu, W et al. [36] | USA | 37 | Female | Melanoma and papillary thyroid cancer | Ipilimumab | No mention | 9 | Clinical+CSF+electrophysiology |
| 25 | Gu, Y et al. [37] | Australia | 49 | Female | Melanoma | Ipilimumab Nivolumab | 5 days (0.7 weeks) | 11 | Clinical+CSF+electrophysiology |
| 26 | Jacob, A et al. [38] | USA | 68 | Female | Lung squamous and cell carcinoma | Nivolumab | 12 weeks | 14 | Clinical+CSF+electrophysiology |
| 27 | Gaudy-Marqueste, C et al. [40] | France | 65 | Male | Melanoma | Ipilimumab | 6 weeks | 11 | Clinical+CSF |
| 28 | Bot, I et al. [41] | Netherlands | 63 | Male | Melanoma | Ipilimumab | 12 weeks | A few days | Clinical+CSF+electrophysiology |
| 29 | Wilgenhof, S et al. [42] | Belgium | 57 | Female | Melanoma | Ipilimumab | 8 weeks | No mention | Clinical + CSF + electrophysiology |
| 30 | de Maleissye, M.F. et al. [39] | France | 45 | Female | Melanoma | Pembrolizumab | 9 weeks | 21 | Clinical+CSF+electrophysiology |
| 31 | Janssen, J.B.E. et al. [42] | Netherlands | 74 | Male | Prostate cancer | Pembrolizumab | 6 weeks | 21 | Clinical+CSF+electrophysiology |
| 32 | Janssen, J.B.E. et al. [13] | Netherlands | 67 | Male | Melanoma | Nivolumab | 3 weeks | 7 | Clinical+CSF |
| 33 | Janssen, J.B.E. et al. [13] | Netherlands | 55 | Male | Melanoma | Pembrolizumab | 16 weeks | 15 | Clinical+CSF |
LEs: lower extremities; UEs: upper extremities; NSCLC: non-small-cell lung cancer; SCLC: small-cell lung cancer; RCC: renal cell carcinoma. Time to Nadir: days between the onset of neurological symptoms and the development of the worst clinical symptoms (no progression).